Report on investor interest in automated cell therapy manufacturing and how factories may scale production to meet clinical demand.
Key Takeaways
- Scaling manufacturing, rather than discovery, will determine cell therapy access and impact
- Cellares' automated Cell Shuttle produced GMP-grade doses that met release specifications and schedules
- If validated, higher automated throughput could substantially reduce manufacturing costs and improve access